Nanomerics Ltd., a clinical-stage speciality pharmaceutical company, has been granted US Patent No. 12,606,641, extending protection of its Molecular Envelope Technology (MET) platform to the 2040s. The grant follows the earlier grant of the corresponding European patent, with further applications pending in other jurisdictions.
A foundational platform for differentiated delivery
MET is the first clinical-stage, non-irritant, topical ocular penetration enhancer. It effectively solubilises hydrophobic drugs and delivers them to both anterior and posterior ocular tissues via topical eye drops. MET also delivers molecules preferentially to the brain via the nose-to-brain route, bypassing the blood-brain barrier.
Applications across the pipeline
MET underpins Nanomerics’ ocular pipeline, including the clinical-stage OC134 — in development for moderate-to-severe allergic conjunctivitis and dry eye disease. MET has also enabled investigational products in moderate-to-severe pain and in the treatment of childhood epilepsies. Its METfect technology has demonstrated extensive pharmacological effects of nucleic-acid-based therapies in the CNS.
Statement from the CEO
“This US grant secures the platform foundation for our current and future MET-based products and reinforces the commercial case we are building with partners.”
— Prof. Andreas G. Schätzlein, CEO
Press enquiries
Pedro Margarido, Head of Operations, Nanomerics Ltd. — pedro.margarido@nanomerics.com